FusionGDB Logo

Home

Download

Statistics

Examples

Help

Contact
Center for Computational Systems Medicine
leaf

Fusion Gene Summary

leaf

Fusion Gene ORF analysis

leaf

Fusion Genomic Features

leaf

Fusion Protein Features

leaf

Fusion Gene Sequence

leaf

Fusion Gene PPI analysis

leaf

Related Drugs

leaf

Related Diseases

Fusion gene:ITPR2-KRAS (FusionGDB2 ID:40523)

Fusion Gene Summary for ITPR2-KRAS

check button Fusion gene summary
Fusion gene informationFusion gene name: ITPR2-KRAS
Fusion gene ID: 40523
HgeneTgene
Gene symbol

ITPR2

KRAS

Gene ID

3709

3845

Gene nameinositol 1,4,5-trisphosphate receptor type 2KRAS proto-oncogene, GTPase
SynonymsANHD|CFAP48|INSP3R2|IP3R2'C-K-RAS|C-K-RAS|CFC2|K-RAS2A|K-RAS2B|K-RAS4A|K-RAS4B|K-Ras|K-Ras 2|KI-RAS|KRAS1|KRAS2|NS|NS3|OES|RALD|RASK2|c-Ki-ras|c-Ki-ras2
Cytomap

12p11.23

12p12.1

Type of geneprotein-codingprotein-coding
Descriptioninositol 1,4,5-trisphosphate receptor type 2IP3 receptorIP3R 2cilia and flagella associated protein 48type 2 InsP3 receptorGTPase KRasK-ras p21 proteinKirsten rat sarcoma viral oncogene homologKirsten rat sarcoma viral proto-oncogenePR310 c-K-ras oncogenec-Kirsten-ras proteincellular c-Ki-ras2 proto-oncogenecellular transforming proto-oncogeneoncogene KRAS2transformi
Modification date2020031320200329
UniProtAcc.

P01116

Ensembl transtripts involved in fusion geneENST00000381340, ENST00000545902, 
ENST00000242737, 		ENST00000311936, 
ENST00000557334, ENST00000256078, 
ENST00000556131, 
Fusion gene scores* DoF score21 X 18 X 10=37806 X 6 X 4=144
# samples 237
** MAII scorelog2(23/3780*10)=-4.03868046816406
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0		log2(7/144*10)=-1.04064198449735
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Context

PubMed: ITPR2 [Title/Abstract] AND KRAS [Title/Abstract] AND fusion [Title/Abstract]

Most frequent breakpointITPR2(26703180)-KRAS(25380346), # samples:1
Anticipated loss of major functional domain due to fusion event.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneITPR2

GO:0001666

response to hypoxia

19120137


check buttonFusion gene breakpoints across ITPR2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

check buttonFusion gene breakpoints across KRAS (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

check button Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0)
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
SourceDiseaseSampleHgeneHchrHbpHstrandTgeneTchrTbpTstrand
ChimerDB4STADTCGA-BR-A4PD-01AITPR2chr12

26703180

-KRASchr12

25380346

-


Top

Fusion Gene ORF analysis for ITPR2-KRAS

check button Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
ORFHenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrand
In-frameENST00000381340ENST00000311936ITPR2chr12

26703180

-KRASchr12

25380346

-
5CDS-intronENST00000381340ENST00000557334ITPR2chr12

26703180

-KRASchr12

25380346

-
5CDS-intronENST00000381340ENST00000256078ITPR2chr12

26703180

-KRASchr12

25380346

-
5CDS-intronENST00000381340ENST00000556131ITPR2chr12

26703180

-KRASchr12

25380346

-
intron-3CDSENST00000545902ENST00000311936ITPR2chr12

26703180

-KRASchr12

25380346

-
intron-intronENST00000545902ENST00000557334ITPR2chr12

26703180

-KRASchr12

25380346

-
intron-intronENST00000545902ENST00000256078ITPR2chr12

26703180

-KRASchr12

25380346

-
intron-intronENST00000545902ENST00000556131ITPR2chr12

26703180

-KRASchr12

25380346

-
intron-3CDSENST00000242737ENST00000311936ITPR2chr12

26703180

-KRASchr12

25380346

-
intron-intronENST00000242737ENST00000557334ITPR2chr12

26703180

-KRASchr12

25380346

-
intron-intronENST00000242737ENST00000256078ITPR2chr12

26703180

-KRASchr12

25380346

-
intron-intronENST00000242737ENST00000556131ITPR2chr12

26703180

-KRASchr12

25380346

-

check buttonORFfinder result based on the fusion transcript sequence of in-frame fusion genes.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)		BP loci
(transcript)		Predicted start
(transcript)		Predicted stop
(transcript)		Seq length
(amino acids)
ENST00000381340ITPR2chr1226703180-ENST00000311936KRASchr1225380346-10952549041759451842

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000381340ENST00000311936ITPR2chr1226703180-KRASchr1225380346-0.0001761590.99982387

Top

Fusion Genomic Features for ITPR2-KRAS


check buttonFusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints.
HgeneHchrHbpHstrandTgeneTchrTbpTstrand1-pp (fusion gene breakpoint)

check buttonDistribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page.

check buttonDistribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page.

Top

Fusion Protein Features for ITPR2-KRAS


check button Go to

FGviewer for the breakpoints of chr12:26703180-chr12:25380346

.
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
FGviewer

check buttonMain function of each fusion partner protein. (from UniProt)
HgeneTgene
.KRAS

P01116

FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes.FUNCTION: Ras proteins bind GDP/GTP and possess intrinsic GTPase activity (PubMed:20949621). Plays an important role in the regulation of cell proliferation (PubMed:23698361, PubMed:22711838). Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner (PubMed:24623306). {ECO:0000269|PubMed:20949621, ECO:0000269|PubMed:22711838, ECO:0000269|PubMed:23698361, ECO:0000269|PubMed:24623306, ECO:0000305}.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at

download page


* Minus value of BPloci means that the break pointn is located before the CDS.
- In-frame and retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
HgeneITPR2chr12:26703180chr12:25380346ENST00000381340-3757112_1661691.02702.0DomainMIR 1
HgeneITPR2chr12:26703180chr12:25380346ENST00000381340-3757173_2231691.02702.0DomainMIR 2
HgeneITPR2chr12:26703180chr12:25380346ENST00000381340-3757231_2871691.02702.0DomainMIR 3
HgeneITPR2chr12:26703180chr12:25380346ENST00000381340-3757294_3721691.02702.0DomainMIR 4
HgeneITPR2chr12:26703180chr12:25380346ENST00000381340-3757378_4341691.02702.0DomainMIR 5
HgeneITPR2chr12:26703180chr12:25380346ENST00000381340-3757265_2691691.02702.0RegionInositol 1%2C4%2C5-trisphosphate binding
HgeneITPR2chr12:26703180chr12:25380346ENST00000381340-3757507_5101691.02702.0RegionInositol 1%2C4%2C5-trisphosphate binding
HgeneITPR2chr12:26703180chr12:25380346ENST00000381340-3757567_5691691.02702.0RegionInositol 1%2C4%2C5-trisphosphate binding
TgeneKRASchr12:26703180chr12:25380346ENST0000025607816116_11937.0333.3333333333333Nucleotide bindingGTP
TgeneKRASchr12:26703180chr12:25380346ENST000002560781659_6037.0333.3333333333333Nucleotide bindingGTP
TgeneKRASchr12:26703180chr12:25380346ENST0000031193615116_11937.0189.0Nucleotide bindingGTP
TgeneKRASchr12:26703180chr12:25380346ENST000003119361559_6037.0189.0Nucleotide bindingGTP
TgeneKRASchr12:26703180chr12:25380346ENST0000025607816166_18537.0333.3333333333333RegionNote=Hypervariable region
TgeneKRASchr12:26703180chr12:25380346ENST0000031193615166_18537.0189.0RegionNote=Hypervariable region

- In-frame and not-retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
HgeneITPR2chr12:26703180chr12:25380346ENST00000242737-16112_1660.0182.0DomainMIR 1
HgeneITPR2chr12:26703180chr12:25380346ENST00000242737-16173_2230.0182.0DomainMIR 2
HgeneITPR2chr12:26703180chr12:25380346ENST00000242737-16231_2870.0182.0DomainMIR 3
HgeneITPR2chr12:26703180chr12:25380346ENST00000242737-16294_3720.0182.0DomainMIR 4
HgeneITPR2chr12:26703180chr12:25380346ENST00000242737-16378_4340.0182.0DomainMIR 5
HgeneITPR2chr12:26703180chr12:25380346ENST00000242737-16265_2690.0182.0RegionInositol 1%2C4%2C5-trisphosphate binding
HgeneITPR2chr12:26703180chr12:25380346ENST00000242737-16507_5100.0182.0RegionInositol 1%2C4%2C5-trisphosphate binding
HgeneITPR2chr12:26703180chr12:25380346ENST00000242737-16567_5690.0182.0RegionInositol 1%2C4%2C5-trisphosphate binding
HgeneITPR2chr12:26703180chr12:25380346ENST00000242737-161_22270.0182.0Topological domainCytoplasmic
HgeneITPR2chr12:26703180chr12:25380346ENST00000242737-162249_22600.0182.0Topological domainExtracellular
HgeneITPR2chr12:26703180chr12:25380346ENST00000242737-162282_23070.0182.0Topological domainCytoplasmic
HgeneITPR2chr12:26703180chr12:25380346ENST00000242737-162329_23510.0182.0Topological domainExtracellular
HgeneITPR2chr12:26703180chr12:25380346ENST00000242737-162373_23940.0182.0Topological domainCytoplasmic
HgeneITPR2chr12:26703180chr12:25380346ENST00000242737-162416_25210.0182.0Topological domainExtracellular
HgeneITPR2chr12:26703180chr12:25380346ENST00000242737-162543_27010.0182.0Topological domainCytoplasmic
HgeneITPR2chr12:26703180chr12:25380346ENST00000381340-37571_22271691.02702.0Topological domainCytoplasmic
HgeneITPR2chr12:26703180chr12:25380346ENST00000381340-37572249_22601691.02702.0Topological domainExtracellular
HgeneITPR2chr12:26703180chr12:25380346ENST00000381340-37572282_23071691.02702.0Topological domainCytoplasmic
HgeneITPR2chr12:26703180chr12:25380346ENST00000381340-37572329_23511691.02702.0Topological domainExtracellular
HgeneITPR2chr12:26703180chr12:25380346ENST00000381340-37572373_23941691.02702.0Topological domainCytoplasmic
HgeneITPR2chr12:26703180chr12:25380346ENST00000381340-37572416_25211691.02702.0Topological domainExtracellular
HgeneITPR2chr12:26703180chr12:25380346ENST00000381340-37572543_27011691.02702.0Topological domainCytoplasmic
HgeneITPR2chr12:26703180chr12:25380346ENST00000242737-162228_22480.0182.0TransmembraneHelical
HgeneITPR2chr12:26703180chr12:25380346ENST00000242737-162261_22810.0182.0TransmembraneHelical
HgeneITPR2chr12:26703180chr12:25380346ENST00000242737-162308_23280.0182.0TransmembraneHelical
HgeneITPR2chr12:26703180chr12:25380346ENST00000242737-162352_23720.0182.0TransmembraneHelical
HgeneITPR2chr12:26703180chr12:25380346ENST00000242737-162395_24150.0182.0TransmembraneHelical
HgeneITPR2chr12:26703180chr12:25380346ENST00000242737-162522_25420.0182.0TransmembraneHelical
HgeneITPR2chr12:26703180chr12:25380346ENST00000381340-37572228_22481691.02702.0TransmembraneHelical
HgeneITPR2chr12:26703180chr12:25380346ENST00000381340-37572261_22811691.02702.0TransmembraneHelical
HgeneITPR2chr12:26703180chr12:25380346ENST00000381340-37572308_23281691.02702.0TransmembraneHelical
HgeneITPR2chr12:26703180chr12:25380346ENST00000381340-37572352_23721691.02702.0TransmembraneHelical
HgeneITPR2chr12:26703180chr12:25380346ENST00000381340-37572395_24151691.02702.0TransmembraneHelical
HgeneITPR2chr12:26703180chr12:25380346ENST00000381340-37572522_25421691.02702.0TransmembraneHelical
TgeneKRASchr12:26703180chr12:25380346ENST000002560781632_4037.0333.3333333333333MotifNote=Effector region
TgeneKRASchr12:26703180chr12:25380346ENST000003119361532_4037.0189.0MotifNote=Effector region
TgeneKRASchr12:26703180chr12:25380346ENST000002560781610_1837.0333.3333333333333Nucleotide bindingGTP
TgeneKRASchr12:26703180chr12:25380346ENST000002560781629_3537.0333.3333333333333Nucleotide bindingGTP
TgeneKRASchr12:26703180chr12:25380346ENST000003119361510_1837.0189.0Nucleotide bindingGTP
TgeneKRASchr12:26703180chr12:25380346ENST000003119361529_3537.0189.0Nucleotide bindingGTP


Top

Fusion Gene Sequence for ITPR2-KRAS


check button For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones.
>In-frame_ENST00000381340_ENST00000311936_TCGA-BR-A4PD-01A_ITPR2_chr12_26703180_-_KRAS_chr12_25380346_length(transcript)=10952nt_BP=5490nt
CTTCCAGCTCCCGCCGGGCGGCTGTGACGGCCGCAGCGGGTCGCAGAGCAGGGAGTGGACACGGAGTGGGGAGCGGAGAGGGAAGGAGGA
GGAGGAGGAGCAAAGGTGTTGGAGAGAAAACTTCAGAAAGGAACAGGAAACCTGCCGGGGAGGCGGCGGCGGCTGCGGCTTCTCTGGGCG
CCTGGGCTGCGCTCTTCGCGGGGTGTCCGCAGCTGCGGCTTGGCCCCGGTCTGGCTTCCCCGGCGCGCACGCACGGCTGAGCCGCGACGC
TCAGTGGCTCGGGCCGTGCCCTCCGCCGCGGCTCTTGGCCGCTGTAGTCCCGCGATCCGATCCGCTTCTGCCGCGGCGGCTCCCTGGAGA
GAGGGCGGCGAGGGCGCAGGGAAGAAGAGGGACGTCCACTGTGGAACATGAAGCAGCATGACTGAGAAAATGTCCAGCTTCCTCTACATA
GGGGACATCGTGTCCCTGTACGCGGAGGGCTCGGTCAACGGCTTCATCAGCACCTTGGGGTTAGTGGATGACAGATGTGTGGTGCACCCA
GAGGCCGGGGACCTTGCCAACCCTCCCAAGAAGTTCAGAGACTGCCTTTTCAAGGTGTGCCCTATGAACAGATATTCTGCCCAGAAGCAA
TATTGGAAAGCAAAGCAAGCCAAACAAGGGAACCACACCGAGGCAGCCTTGCTGAAGAAACTACAGCACGCTGCAGAACTGGAACAAAAA
CAAAATGAATCGGAGAATAAGAAACTGTTGGGAGAAATTGTAAAATACAGTAATGTTATACAACTACTGCATATAAAAAGCAACAAATAT
CTTACTGTCAACAAGAGATTACCTGCTTTACTGGAGAAGAATGCCATGCGTGTGTCCTTGGATGCTGCAGGAAATGAAGGGTCTTGGTTT
TATATTCATCCGTTCTGGAAACTGAGAAGCGAGGGTGACAATATTGTTGTAGGAGATAAAGTTGTTTTGATGCCTGTGAATGCAGGGCAG
CCACTACATGCCAGCAACATAGAGCTTCTTGATAACCCAGGGTGTAAAGAGGTGAATGCTGTCAATTGCAACACCAGCTGGAAAATCACT
TTATTCATGAAATATAGTTCCTATCGAGAGGATGTATTAAAAGGAGGGGACGTTGTTAGATTATTTCATGCGGAACAAGAGAAGTTTTTG
ACTTGTGATGAATATGAGAAAAAACAGCACATTTTCCTTCGTACGACCTTGCGCCAATCAGCTACTTCTGCTACTAGTTCTAAAGCACTC
TGGGAAATAGAGGTGGTTCATCATGACCCATGCCGTGGGGGTGCAGGACAGTGGAACAGCTTGTTCAGATTTAAGCATCTTGCAACTGGA
AACTATTTAGCTGCAGAGCTTAATCCTGATTATCGAGATGCCCAAAATGAAGGAAAAAATGTGAGAGATGGAGTCCCTCCAACTTCAAAG
AAAAAACGCCAGGCAGGGGAGAAGATCATGTATACTTTGGTTTCAGTCCCGCATGGCAATGACATTGCATCCCTTTTTGAACTAGATGCC
ACAACTCTTCAGAGAGCTGACTGCCTGGTTCCAAGGAACTCATATGTTCGGTTAAGGCATTTATGCACCAACACATGGGTAACCAGTACT
AGTATCCCCATAGACACAGATGAAGAGAGGCCTGTTATGTTAAAGATTGGAACCTGCCAAACCAAAGAAGATAAAGAAGCGTTCGCAATC
GTGTCTGTTCCACTGTCTGAAGTTCGAGACTTAGACTTTGCCAATGATGCCAATAAAGTACTAGCGACCACAGTTAAAAAGCTAGAAAAC
GGCACAATAACTCAGAATGAAAGGAGGTTTGTAACCAAATTATTGGAAGATCTCATATTCTTTGTTGCTGATGTGCCTAATAATGGACAA
GAAGTTCTGGATGTGGTTATCACTAAGCCAAACCGAGAGCGTCAAAAATTGATGAGGGAACAAAACATACTGGCACAGGTATTTGGAATT
CTTAAAGCACCCTTTAAAGAGAAAGCAGGAGAAGGCTCGATGCTGAGACTTGAAGATCTGGGGGATCAAAGATATGCACCCTACAAGTAC
ATGCTGCGGCTCTGTTACCGCGTCCTGAGACACTCGCAGCAGGATTACCGGAAAAATCAGGAATATATTGCTAAGAATTTCTGTGTCATG
CAGTCCCAGATTGGCTATGATATTTTGGCAGAAGATACTATCACAGCTTTGTTGCACAACAACAGAAAACTACTAGAGAAACATATCACA
GCAAAAGAAATAGAAACATTTGTCAGTTTACTCAGGAGAAATCGGGAGCCAAGGTTTTTGGATTATTTGTCAGATCTGTGTGTGTCTAAT
ACCACTGCTATCCCTGTAACTCAAGAACTCATCTGTAAATTTATGTTGAGTCCAGGCAATGCAGACATTCTCATTCAAACTAAGGTGGTC
TCAATGCAAGCAGACAACCCCATGGAGAGCTCCATCCTTTCAGATGACATTGATGATGAAGAAGTTTGGCTCTATTGGATTGACAGCAAC
AAGGAACCTCATGGCAAAGCTATCAGGCACCTTGCTCAAGAGGCAAAAGAAGGCACCAAAGCTGACTTAGAAGTTCTTACCTATTACAGG
TACCAGCTAAACCTCTTTGCAAGGATGTGCTTGGATCGCCAGTATCTGGCCATAAACCAGATTTCTACACAGCTGTCTGTAGACCTGATC
CTGCGGTGTGTGTCGGATGAGAGCCTGCCGTTCGACCTCCGAGCGTCCTTCTGTCGCCTCATGCTCCACATGCACGTTGACCGGGATCCC
CAGGAGTCCGTGGTGCCTGTTCGCTATGCCAGGCTCTGGACAGAAATCCCCACAAAGATCACAATTCATGAATATGATTCTATAACAGAC
TCTTCCAGAAATGATATGAAGAGGAAATTTGCCCTGACAATGGAATTTGTTGAAGAATATTTGAAAGAAGTTGTAAACCAGCCCTTTCCT
TTTGGGGATAAAGAAAAAAATAAACTGACATTTGAGGTGGTCCACTTGGCTCGGAATCTTATATACTTTGGATTTTATAGTTTCAGTGAG
TTATTAAGGCTAACAAGAACACTTCTGGCTATTTTAGACATTGTACAGGCCCCCATGTCATCATACTTTGAAAGATTAAGCAAATTTCAA
GATGGAGGAAACAATGTGATGAGAACCATTCATGGGGTGGGAGAGATGATGACCCAGATGGTACTCAGTAGAGGCTCCATCTTCCCCATG
AGCGTGCCGGATGTGCCACCCAGCATCCACCCGAGCAAGCAAGGGAGCCCCACCGAGCACGAGGATGTGACTGTGATGGACACCAAGCTG
AAGATCATTGAGATTTTGCAGTTTATCCTGAGTGTCAGACTGGATTATAGGATCTCATATATGCTGTCAATATATAAGAAGGAGTTTGGA
GAGGACAATGACAATGCGGAGACATCTGCCAGTGGATCTCCAGACACTTTACTACCATCAGCTATTGTTCCTGATATAGATGAAATTGCA
GCTCAGGCAGAAACTATGTTTGCGGGAAGAAAAGAAAAAAATCCAGTTCAACTTGACGATGAAGGAGGCAGGACGTTTTTACGGGTCCTC
ATTCATCTGATCATGCACGACTACCCGCCTTTGCTGTCTGGAGCCCTGCAGCTGTTGTTTAAGCACTTCAGCCAGAGGGCAGAGGTTTTA
CAGGCATTTAAGCAGGTGCAATTACTGGTGTCTAATCAAGACGTAGATAACTACAAGCAAATCAAGGCAGATCTAGACCAGCTTCGACTG
ACAGTAGAAAAGTCTGAGCTATGGGTGGAGAAGAGCAGCAACTATGAGAATGGAGAAATAGGGGAAAGTCAAGTGAAAGGTGGTGAAGAG
CCAATTGAGGAATCAAACATTTTAAGTCCAGTGCAGGATGGAACAAAGAAACCTCAGATTGACAGCAACAAGAGCAATAACTACCGGATT
GTAAAGGAGATTTTGATCAGGCTAAGTAAACTCTGTGTGCAGAATAAAAAGTGTCGGAATCAACATCAACGATTACTGAAAAATATGGGG
GCGCATTCGGTGGTGTTGGATCTTCTGCAGATACCCTATGAAAAGAATGATGAAAAGATGAATGAAGTAATGAATCTAGCCCATACATTT
CTGCAGAATTTCTGTCGAGGAAATCCACAGAATCAAGTTCTTCTTCATAAACATCTGAATTTGTTTTTAACTCCAGGTCTCCTTGAAGCA
GAAACCATGCGGCACATCTTCATGAACAATTACCATCTGTGCAACGAAATTAGCGAGAGAGTTGTACAACACTTTGTGCACTGCATTGAG
ACACATGGCCGCCACGTGGAGTACCTGAGGTTTTTGCAAACAATTGTAAAAGCAGATGGTAAATATGTGAAGAAATGCCAGGATATGGTA
ATGACAGAGTTGATAAATGGGGGTGAAGACGTGCTGATATTTTACAATGATAGAGCATCATTTCCAATCCTTCTCCATATGATGTGTTCA
GAGAGAGACCGAGGGGATGAGAGTGGCCCCTTAGCCTACCACATCACCCTGGTGGAGTTGCTGGCAGCATGCACAGAGGGGAAAAATGTC
TACACTGAAATCAAGTGTAATTCCCTTCTCCCGCTGGACGACATAGTGAGGGTGGTGACCCATGACGACTGCATCCCTGAGGTTAAAATT
GCTTATGTGAACTTTGTTAATCACTGTTATGTTGACACTGAAGTGGAAATGAAAGAAATCTATACAAGTAACCACATTTGGAAATTATTT
GAGAACTTCTTGGTGGATATGGCAAGGGTTTGCAACACAACTACAGACAGGAAACATGCAGACATCTTTTTGGAAAAGTGTGTTACTGAG
TCAATAATGAATATTGTGAGCGGCTTCTTTAATTCTCCCTTTTCAGACAATAGTACCAGCCTCCAGACACATCAGCCAGTTTTTATTCAG
CTACTGCAATCTGCCTTCAGAATTTACAATTGCACCTGGCCAAACCCAGCGCAGAAAGCCTCAGTGGAATCCTGTATCAGAACTTTGGCT
GAAGTGGCAAAAAATCGTGGAATTGCCATTCCAGTGGATTTGGACAGCCAAGTTAATACTCTTTTCATGAAGAGCCATTCAAATATGGTG
CAGAGAGCAGCAATGGGTTGGAGACTATCAGCTCGCTCTGGGCCACGCTTTAAGGAAGCTCTTGGAGGGCCTGCTTGGGATTACAGAAAT
ATTATTGAAAAGTTACAGGATGTAGTGGCCTCCTTGGAGCACCAGTTCAGCCCAATGATGCAGGCTGAATTCTCAGTGTTGGTTGATGTA
TTGTACAGTCCAGAACTGCTGTTCCCTGAGGGAAGCGATGCAAGAATAAGATGTGGCGCTTTCATGTCGAAGTTGATTAATCATACAAAG
AAACTAATGGAGAAAGAAGAAAAACTGTGCATTAAAATTCTTCAGACATTACGAGAAATGTTAGAGAAGAAAGACAGCTTTGTGGAAGAG
GATTCCTACAGGAAGCAAGTAGTAATTGATGGAGAAACCTGTCTCTTGGATATTCTCGACACAGCAGGTCAAGAGGAGTACAGTGCAATG
AGGGACCAGTACATGAGGACTGGGGAGGGCTTTCTTTGTGTATTTGCCATAAATAATACTAAATCATTTGAAGATATTCACCATTATAGA
GAACAAATTAAAAGAGTTAAGGACTCTGAAGATGTACCTATGGTCCTAGTAGGAAATAAATGTGATTTGCCTTCTAGAACAGTAGACACA
AAACAGGCTCAGGACTTAGCAAGAAGTTATGGAATTCCTTTTATTGAAACATCAGCAAAGACAAGACAGGGTGTTGATGATGCCTTCTAT
ACATTAGTTCGAGAAATTCGAAAACATAAAGAAAAGATGAGCAAAGATGGTAAAAAGAAGAAAAAGAAGTCAAAGACAAAGTGTGTAATT
ATGTAAATACAATTTGTACTTTTTTCTTAAGGCATACTAGTACAAGTGGTAATTTTTGTACATTACACTAAATTATTAGCATTTGTTTTA
GCATTACCTAATTTTTTTCCTGCTCCATGCAGACTGTTAGCTTTTACCTTAAATGCTTATTTTAAAATGACAGTGGAAGTTTTTTTTTCC
TCTAAGTGCCAGTATTCCCAGAGTTTTGGTTTTTGAACTAGCAATGCCTGTGAAAAAGAAACTGAATACCTAAGATTTCTGTCTTGGGGC
TTTTGGTGCATGCAGTTGATTACTTCTTATTTTTCTTACCAATTGTGAATGTTGGTGTGAAACAAATTAATGAAGCTTTTGAATCATCCC
TATTCTGTGTTTTATCTAGTCACATAAATGGATTAATTACTAATTTCAGTTGAGACCTTCTAATTGGTTTTTACTGAAACATTGAGGGAA
CACAAATTTATGGGCTTCCTGATGATGATTCTTCTAGGCATCATGTCCTATAGTTTGTCATCCCTGATGAATGTAAAGTTACACTGTTCA
CAAAGGTTTTGTCTCCTTTCCACTGCTATTAGTCATGGTCACTCTCCCCAAAATATTATATTTTTTCTATAAAAAGAAAAAAATGGAAAA
AAATTACAAGGCAATGGAAACTATTATAAGGCCATTTCCTTTTCACATTAGATAAATTACTATAAAGACTCCTAATAGCTTTTCCTGTTA
AGGCAGACCCAGTATGAAATGGGGATTATTATAGCAACCATTTTGGGGCTATATTTACATGCTACTAAATTTTTATAATAATTGAAAAGA
TTTTAACAAGTATAAAAAATTCTCATAGGAATTAAATGTAGTCTCCCTGTGTCAGACTGCTCTTTCATAGTATAACTTTAAATCTTTTCT
TCAACTTGAGTCTTTGAAGATAGTTTTAATTCTGCTTGTGACATTAAAAGATTATTTGGGCCAGTTATAGCTTATTAGGTGTTGAAGAGA
CCAAGGTTGCAAGGCCAGGCCCTGTGTGAACCTTTGAGCTTTCATAGAGAGTTTCACAGCATGGACTGTGTCCCCACGGTCATCCAGTGT
TGTCATGCATTGGTTAGTCAAAATGGGGAGGGACTAGGGCAGTTTGGATAGCTCAACAAGATACAATCTCACTCTGTGGTGGTCCTGCTG
ACAAATCAAGAGCATTGCTTTTGTTTCTTAAGAAAACAAACTCTTTTTTAAAAATTACTTTTAAATATTAACTCAAAAGTTGAGATTTTG
GGGTGGTGGTGTGCCAAGACATTAATTTTTTTTTTAAACAATGAAGTGAAAAAGTTTTACAATCTCTAGGTTTGGCTAGTTCTCTTAACA
CTGGTTAAATTAACATTGCATAAACACTTTTCAAGTCTGATCCATATTTAATAATGCTTTAAAATAAAAATAAAAACAATCCTTTTGATA
AATTTAAAATGTTACTTATTTTAAAATAAATGAAGTGAGATGGCATGGTGAGGTGAAAGTATCACTGGACTAGGAAGAAGGTGACTTAGG
TTCTAGATAGGTGTCTTTTAGGACTCTGATTTTGAGGACATCACTTACTATCCATTTCTTCATGTTAAAAGAAGTCATCTCAAACTCTTA
GTTTTTTTTTTTTACAACTATGTAATTTATATTCCATTTACATAAGGATACACTTATTTGTCAAGCTCAGCACAATCTGTAAATTTTTAA
CCTATGTTACACCATCTTCAGTGCCAGTCTTGGGCAAAATTGTGCAAGAGGTGAAGTTTATATTTGAATATCCATTCTCGTTTTAGGACT
CTTCTTCCATATTAGTGTCATCTTGCCTCCCTACCTTCCACATGCCCCATGACTTGATGCAGTTTTAATACTTGTAATTCCCCTAACCAT
AAGATTTACTGCTGCTGTGGATATCTCCATGAAGTTTTCCCACTGAGTCACATCAGAAATGCCCTACATCTTATTTCCTCAGGGCTCAAG
AGAATCTGACAGATACCATAAAGGGATTTGACCTAATCACTAATTTTCAGGTGGTGGCTGATGCTTTGAACATCTCTTTGCTGCCCAATC
CATTAGCGACAGTAGGATTTTTCAAACCTGGTATGAATAGACAGAACCCTATCCAGTGGAAGGAGAATTTAATAAAGATAGTGCTGAAAG
AATTCCTTAGGTAATCTATAACTAGGACTACTCCTGGTAACAGTAATACATTCCATTGTTTTAGTAACCAGAAATCTTCATGCAATGAAA
AATACTTTAATTCATGAAGCTTACTTTTTTTTTTTGGTGTCAGAGTCTCGCTCTTGTCACCCAGGCTGGAATGCAGTGGCGCCATCTCAG
CTCACTGCAACCTCCATCTCCCAGGTTCAAGCGATTCTCGTGCCTCGGCCTCCTGAGTAGCTGGGATTACAGGCGTGTGCCACTACACTC
AACTAATTTTTGTATTTTTAGGAGAGACGGGGTTTCACCCTGTTGGCCAGGCTGGTCTCGAACTCCTGACCTCAAGTGATTCACCCACCT
TGGCCTCATAAACCTGTTTTGCAGAACTCATTTATTCAGCAAATATTTATTGAGTGCCTACCAGATGCCAGTCACCACACAAGGCACTGG
GTATATGGTATCCCCAAACAAGAGACATAATCCCGGTCCTTAGGTAGTGCTAGTGTGGTCTGTAATATCTTACTAAGGCCTTTGGTATAC
GACCCAGAGATAACACGATGCGTATTTTAGTTTTGCAAAGAAGGGGTTTGGTCTCTGTGCCAGCTCTATAATTGTTTTGCTACGATTCCA
CTGAAACTCTTCGATCAAGCTACTTTATGTAAATCACTTCATTGTTTTAAAGGAATAAACTTGATTATATTGTTTTTTTATTTGGCATAA
CTGTGATTCTTTTAGGACAATTACTGTACACATTAAGGTGTATGTCAGATATTCATATTGACCCAAATGTGTAATATTCCAGTTTTCTCT
GCATAAGTAATTAAAATATACTTAAAAATTAATAGTTTTATCTGGGTACAAATAAACAGGTGCCTGAACTAGTTCACAGACAAGGAAACT
TCTATGTAAAAATCACTATGATTTCTGAATTGCTATGTGAAACTACAGATCTTTGGAACACTGTTTAGGTAGGGTGTTAAGACTTACACA
GTACCTCGTTTCTACACAGAGAAAGAAATGGCCATACTTCAGGAACTGCAGTGCTTATGAGGGGATATTTAGGCCTCTTGAATTTTTGAT
GTAGATGGGCATTTTTTTAAGGTAGTGGTTAATTACCTTTATGTGAACTTTGAATGGTTTAACAAAAGATTTGTTTTTGTAGAGATTTTA
AAGGGGGAGAATTCTAGAAATAAATGTTACCTAATTATTACAGCCTTAAAGACAAAAATCCTTGTTGAAGTTTTTTTAAAAAAAGCTAAA
TTACATAGACTTAGGCATTAACATGTTTGTGGAAGAATATAGCAGACGTATATTGTATCATTTGAGTGAATGTTCCCAAGTAGGCATTCT
AGGCTCTATTTAACTGAGTCACACTGCATAGGAATTTAGAACCTAACTTTTATAGGTTATCAAAACTGTTGTCACCATTGCACAATTTTG
TCCTAATATATACATAGAAACTTTGTGGGGCATGTTAAGTTACAGTTTGCACAAGTTCATCTCATTTGTATTCCATTGATTTTTTTTTTC
TTCTAAACATTTTTTCTTCAAACAGTATATAACTTTTTTTAGGGGATTTTTTTTTAGACAGCAAAAACTATCTGAAGATTTCCATTTGTC
AAAAAGTAATGATTTCTTGATAATTGTGTAGTAATGTTTTTTAGAACCCAGCAGTTACCTTAAAGCTGAATTTATATTTAGTAACTTCTG
TGTTAATACTGGATAGCATGAATTCTGCATTGAGAAACTGAATAGCTGTCATAAAATGAAACTTTCTTTCTAAAGAAAGATACTCACATG
AGTTCTTGAAGAATAGTCATAACTAGATTAAGATCTGTGTTTTAGTTTAATAGTTTGAAGTGCCTGTTTGGGATAATGATAGGTAATTTA
GATGAATTTAGGGGAAAAAAAAGTTATCTGCAGATATGTTGAGGGCCCATCTCTCCCCCCACACCCCCACAGAGCTAACTGGGTTACAGT
GTTTTATCCGAAAGTTTCCAATTCCACTGTCTTGTGTTTTCATGTTGAAAATACTTTTGCATTTTTCCTTTGAGTGCCAATTTCTTACTA
GTACTATTTCTTAATGTAACATGTTTACCTGGAATGTATTTTAACTATTTTTGTATAGTGTAAACTGAAACATGCACATTTTGTACATTG
TGCTTTCTTTTGTGGGACATATGCAGTGTGATCCAGTTGTTTTCCATCATTTGGTTGCGCTGACCTAGGAATGTTGGTCATATCAAACAT
TAAAAATGACCACTCTTTTAATTGAAATTAACTTTTAAATGTTTATAGGAGTATGTGCTGTGAAGTGATCTAAAATTTGTAATATTTTTG
TCATGAACTGTACTACTCCTAATTATTGTAATGTAATAAAAATAGTTACAGTGACTATGAGTGTGTATTTATTCATGAAATTTGAACTGT
TTGCCCCGAAATGGATATGGAATACTTTATAAGCCATAGACACTATAGTATACCAGTGAATCTTTTATGCAGCTTGTTAGAAGTATCCTT
TATTTCTAAAAGGTGCTGTGGATATTATGTAAAGGCGTGTTTGCTTAAACTTAAAACCATATTTAGAAGTAGATGCAAAACAAATCTGCC
TTTATGACAAAAAAATAGGATAACATTATTTATTTATTTCCTTTTATCAAAGAAGGTAATTGATACACAACAGGTGACTTGGTTTTAGGC
CCAAAGGTAGCAGCAGCAACATTAATAATGGAAATAATTGAATAGTTAGTTATGTATGTTAATGCCAGTCACCAGCAGGCTATTTCAAGG

>In-frame_ENST00000381340_ENST00000311936_TCGA-BR-A4PD-01A_ITPR2_chr12_26703180_-_KRAS_chr12_25380346_length(amino acids)=1842AA_start in transcript=417_stop in transcript=5945
MTEKMSSFLYIGDIVSLYAEGSVNGFISTLGLVDDRCVVHPEAGDLANPPKKFRDCLFKVCPMNRYSAQKQYWKAKQAKQGNHTEAALLK
KLQHAAELEQKQNESENKKLLGEIVKYSNVIQLLHIKSNKYLTVNKRLPALLEKNAMRVSLDAAGNEGSWFYIHPFWKLRSEGDNIVVGD
KVVLMPVNAGQPLHASNIELLDNPGCKEVNAVNCNTSWKITLFMKYSSYREDVLKGGDVVRLFHAEQEKFLTCDEYEKKQHIFLRTTLRQ
SATSATSSKALWEIEVVHHDPCRGGAGQWNSLFRFKHLATGNYLAAELNPDYRDAQNEGKNVRDGVPPTSKKKRQAGEKIMYTLVSVPHG
NDIASLFELDATTLQRADCLVPRNSYVRLRHLCTNTWVTSTSIPIDTDEERPVMLKIGTCQTKEDKEAFAIVSVPLSEVRDLDFANDANK
VLATTVKKLENGTITQNERRFVTKLLEDLIFFVADVPNNGQEVLDVVITKPNRERQKLMREQNILAQVFGILKAPFKEKAGEGSMLRLED
LGDQRYAPYKYMLRLCYRVLRHSQQDYRKNQEYIAKNFCVMQSQIGYDILAEDTITALLHNNRKLLEKHITAKEIETFVSLLRRNREPRF
LDYLSDLCVSNTTAIPVTQELICKFMLSPGNADILIQTKVVSMQADNPMESSILSDDIDDEEVWLYWIDSNKEPHGKAIRHLAQEAKEGT
KADLEVLTYYRYQLNLFARMCLDRQYLAINQISTQLSVDLILRCVSDESLPFDLRASFCRLMLHMHVDRDPQESVVPVRYARLWTEIPTK
ITIHEYDSITDSSRNDMKRKFALTMEFVEEYLKEVVNQPFPFGDKEKNKLTFEVVHLARNLIYFGFYSFSELLRLTRTLLAILDIVQAPM
SSYFERLSKFQDGGNNVMRTIHGVGEMMTQMVLSRGSIFPMSVPDVPPSIHPSKQGSPTEHEDVTVMDTKLKIIEILQFILSVRLDYRIS
YMLSIYKKEFGEDNDNAETSASGSPDTLLPSAIVPDIDEIAAQAETMFAGRKEKNPVQLDDEGGRTFLRVLIHLIMHDYPPLLSGALQLL
FKHFSQRAEVLQAFKQVQLLVSNQDVDNYKQIKADLDQLRLTVEKSELWVEKSSNYENGEIGESQVKGGEEPIEESNILSPVQDGTKKPQ
IDSNKSNNYRIVKEILIRLSKLCVQNKKCRNQHQRLLKNMGAHSVVLDLLQIPYEKNDEKMNEVMNLAHTFLQNFCRGNPQNQVLLHKHL
NLFLTPGLLEAETMRHIFMNNYHLCNEISERVVQHFVHCIETHGRHVEYLRFLQTIVKADGKYVKKCQDMVMTELINGGEDVLIFYNDRA
SFPILLHMMCSERDRGDESGPLAYHITLVELLAACTEGKNVYTEIKCNSLLPLDDIVRVVTHDDCIPEVKIAYVNFVNHCYVDTEVEMKE
IYTSNHIWKLFENFLVDMARVCNTTTDRKHADIFLEKCVTESIMNIVSGFFNSPFSDNSTSLQTHQPVFIQLLQSAFRIYNCTWPNPAQK
ASVESCIRTLAEVAKNRGIAIPVDLDSQVNTLFMKSHSNMVQRAAMGWRLSARSGPRFKEALGGPAWDYRNIIEKLQDVVASLEHQFSPM
MQAEFSVLVDVLYSPELLFPEGSDARIRCGAFMSKLINHTKKLMEKEEKLCIKILQTLREMLEKKDSFVEEDSYRKQVVIDGETCLLDIL
DTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSA

--------------------------------------------------------------

Top

Fusion Gene PPI Analysis for ITPR2-KRAS


check button Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in

ChiPPI page.


check button Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160)
HgeneHgene's interactorsTgeneTgene's interactors


check button - Retained PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenStill interaction with


check button - Lost PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


check button - Retained PPIs, but lost function due to frame-shift fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


Top

Related Drugs for ITPR2-KRAS


check button Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.8 2021-05-08)
PartnerGeneUniProtAccDrugBank IDDrug nameDrug activityDrug typeDrug status

Top

Related Diseases for ITPR2-KRAS


check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgeneITPR2C0003132Anoxic Encephalopathy1CTD_human
HgeneITPR2C0018800Cardiomegaly1CTD_human
HgeneITPR2C0995195Anoxia of brain1CTD_human
HgeneITPR2C1140716Hypoxic Brain Damage1CTD_human
HgeneITPR2C1383860Cardiac Hypertrophy1CTD_human
HgeneITPR2C1527348Brain Hypoxia1CTD_human
HgeneITPR2C1862871ANHIDROSIS, ISOLATED, WITH NORMAL SWEAT GLANDS1CTD_human;ORPHANET;UNIPROT
TgeneKRASC0024121Lung Neoplasms33CGI;CTD_human
TgeneKRASC0242379Malignant neoplasm of lung33CGI;CTD_human;UNIPROT
TgeneKRASC0028326Noonan Syndrome13CLINGEN;CTD_human;GENOMICS_ENGLAND;ORPHANET
TgeneKRASC1275081Cardio-facio-cutaneous syndrome12CLINGEN;CTD_human;GENOMICS_ENGLAND;ORPHANET
TgeneKRASC3809005CARDIOFACIOCUTANEOUS SYNDROME 210GENOMICS_ENGLAND;UNIPROT
TgeneKRASC1860991NOONAN SYNDROME 39CTD_human;GENOMICS_ENGLAND;UNIPROT
TgeneKRASC0007131Non-Small Cell Lung Carcinoma7CGI;CTD_human
TgeneKRASC0007102Malignant tumor of colon6CTD_human
TgeneKRASC0009375Colonic Neoplasms6CTD_human
TgeneKRASC0030297Pancreatic Neoplasm6CGI;CTD_human
TgeneKRASC0346647Malignant neoplasm of pancreas6CGI;CTD_human
TgeneKRASC0027659Neoplasms, Experimental5CTD_human
TgeneKRASC0152013Adenocarcinoma of lung (disorder)5CGI;CTD_human
TgeneKRASC0001430Adenoma4CTD_human
TgeneKRASC0018923Hemangiosarcoma4CGI;CTD_human
TgeneKRASC0041409Turner Syndrome, Male4CTD_human
TgeneKRASC0205646Adenoma, Basal Cell4CTD_human
TgeneKRASC0205647Follicular adenoma4CTD_human
TgeneKRASC0205648Adenoma, Microcystic4CTD_human
TgeneKRASC0205649Adenoma, Monomorphic4CTD_human
TgeneKRASC0205650Papillary adenoma4CTD_human
TgeneKRASC0205651Adenoma, Trabecular4CTD_human
TgeneKRASC0238463Papillary thyroid carcinoma4ORPHANET
TgeneKRASC0349639Juvenile Myelomonocytic Leukemia4CTD_human;ORPHANET;UNIPROT
TgeneKRASC0587248Costello syndrome (disorder)4CLINGEN;CTD_human
TgeneKRASC1519086Pilomyxoid astrocytoma4ORPHANET
TgeneKRASC1527404Female Pseudo-Turner Syndrome4CTD_human
TgeneKRASC4551602Noonan Syndrome 14CTD_human
TgeneKRASC0001418Adenocarcinoma3CTD_human
TgeneKRASC0009402Colorectal Carcinoma3CTD_human;UNIPROT
TgeneKRASC0009404Colorectal Neoplasms3CTD_human
TgeneKRASC0205641Adenocarcinoma, Basal Cell3CTD_human
TgeneKRASC0205642Adenocarcinoma, Oxyphilic3CTD_human
TgeneKRASC0205643Carcinoma, Cribriform3CTD_human
TgeneKRASC0205644Carcinoma, Granular Cell3CTD_human
TgeneKRASC0205645Adenocarcinoma, Tubular3CTD_human
TgeneKRASC0699791Stomach Carcinoma3UNIPROT
TgeneKRASC0006826Malignant Neoplasms2CGI;CTD_human
TgeneKRASC0007097Carcinoma2CTD_human
TgeneKRASC0007137Squamous cell carcinoma2CTD_human
TgeneKRASC0023903Liver neoplasms2CTD_human
TgeneKRASC0024623Malignant neoplasm of stomach2CTD_human
TgeneKRASC0027651Neoplasms2CTD_human
TgeneKRASC0038356Stomach Neoplasms2CTD_human
TgeneKRASC0086692Benign Neoplasm2CTD_human
TgeneKRASC0205696Anaplastic carcinoma2CTD_human
TgeneKRASC0205697Carcinoma, Spindle-Cell2CTD_human
TgeneKRASC0205698Undifferentiated carcinoma2CTD_human
TgeneKRASC0205699Carcinomatosis2CTD_human
TgeneKRASC0206698Cholangiocarcinoma2CTD_human
TgeneKRASC0345904Malignant neoplasm of liver2CTD_human
TgeneKRASC0345905Intrahepatic Cholangiocarcinoma2CTD_human
TgeneKRASC0596263Carcinogenesis2CTD_human
TgeneKRASC0887833Carcinoma, Pancreatic Ductal2CTD_human
TgeneKRASC1708349Hereditary Diffuse Gastric Cancer2CTD_human
TgeneKRASC2239176Liver carcinoma2CTD_human
TgeneKRASC2674723RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER2GENOMICS_ENGLAND;ORPHANET
TgeneKRASC3805278Extrahepatic Cholangiocarcinoma2CTD_human
TgeneKRASC0002871Anemia1CTD_human
TgeneKRASC0004114Astrocytoma1CTD_human
TgeneKRASC0005684Malignant neoplasm of urinary bladder1CTD_human;UNIPROT
TgeneKRASC0005695Bladder Neoplasm1CTD_human
TgeneKRASC0007528Cecal Neoplasms1CTD_human
TgeneKRASC0007621Neoplastic Cell Transformation1CTD_human
TgeneKRASC0014175Endometriosis1CTD_human
TgeneKRASC0016978gallbladder neoplasm1CTD_human
TgeneKRASC0019207Hepatoma, Morris1CTD_human
TgeneKRASC0019208Hepatoma, Novikoff1CTD_human
TgeneKRASC0023518Leukocytosis1CTD_human
TgeneKRASC0023897Liver Diseases, Parasitic1CTD_human
TgeneKRASC0023904Liver Neoplasms, Experimental1CTD_human
TgeneKRASC0024299Lymphoma1CTD_human
TgeneKRASC0026640Mouth Neoplasms1CTD_human
TgeneKRASC0027627Neoplasm Metastasis1CTD_human
TgeneKRASC0027819Neuroblastoma1CTD_human
TgeneKRASC0030849Penile Neoplasms1CTD_human
TgeneKRASC0033578Prostatic Neoplasms1CTD_human
TgeneKRASC0038002Splenomegaly1CTD_human
TgeneKRASC0040136Thyroid Neoplasm1CGI;CTD_human
TgeneKRASC0042138Uterine Neoplasms1CTD_human
TgeneKRASC0086404Experimental Hepatoma1CTD_human
TgeneKRASC0087031Juvenile-Onset Still Disease1CTD_human
TgeneKRASC0151468Thyroid Gland Follicular Adenoma1CTD_human
TgeneKRASC0151857Pleocytosis1CTD_human
TgeneKRASC0153381Malignant neoplasm of mouth1CTD_human
TgeneKRASC0153437Malignant neoplasm of cecum1CTD_human
TgeneKRASC0153452Malignant neoplasm of gallbladder1CTD_human
TgeneKRASC0153567Uterine Cancer1CTD_human
TgeneKRASC0153601Malignant neoplasm of penis1CTD_human
TgeneKRASC0205768Subependymal Giant Cell Astrocytoma1CTD_human
TgeneKRASC0206682Follicular thyroid carcinoma1CTD_human
TgeneKRASC0235874Disease Exacerbation1CTD_human
TgeneKRASC0265329Organoid Nevus Phakomatosis1CTD_human;GENOMICS_ENGLAND;ORPHANET
TgeneKRASC0269102Endometrioma1CTD_human
TgeneKRASC0280783Juvenile Pilocytic Astrocytoma1CTD_human
TgeneKRASC0280785Diffuse Astrocytoma1CTD_human
TgeneKRASC0334579Anaplastic astrocytoma1CTD_human
TgeneKRASC0334580Protoplasmic astrocytoma1CTD_human
TgeneKRASC0334581Gemistocytic astrocytoma1CTD_human
TgeneKRASC0334582Fibrillary Astrocytoma1CTD_human
TgeneKRASC0334583Pilocytic Astrocytoma1CGI;CTD_human
TgeneKRASC0338070Childhood Cerebral Astrocytoma1CTD_human
TgeneKRASC0362030Verrucous epidermal nevus1CTD_human
TgeneKRASC0376358Malignant neoplasm of prostate1CTD_human
TgeneKRASC0406612Encephalocraniocutaneous lipomatosis1ORPHANET
TgeneKRASC0473574Inflammatory linear verrucous epidermal nevus1CTD_human
TgeneKRASC0547065Mixed oligoastrocytoma1CTD_human
TgeneKRASC0549473Thyroid carcinoma1CGI;CTD_human
TgeneKRASC0750935Cerebral Astrocytoma1CTD_human
TgeneKRASC0750936Intracranial Astrocytoma1CTD_human
TgeneKRASC0919267ovarian neoplasm1CGI;CTD_human
TgeneKRASC1112155Hereditary non-polyposis colorectal cancer syndrome1ORPHANET
TgeneKRASC1140680Malignant neoplasm of ovary1CGI;CTD_human
TgeneKRASC1333990Hereditary Nonpolyposis Colorectal Cancer1ORPHANET
TgeneKRASC1704230Grade I Astrocytoma1CTD_human
TgeneKRASC1838329APLASIA CUTIS CONGENITA WITH EPIBULBAR DERMOIDS1ORPHANET
TgeneKRASC2713368Hematopoetic Myelodysplasia1CTD_human
TgeneKRASC2931038Pancreatic carcinoma, familial1ORPHANET
TgeneKRASC2931822Nasopharyngeal carcinoma1CTD_human
TgeneKRASC3179502Linear Verrucous Epidermal Nevus1CTD_human
TgeneKRASC3463824MYELODYSPLASTIC SYNDROME1CTD_human
TgeneKRASC3495559Juvenile arthritis1CTD_human
TgeneKRASC3539878Triple Negative Breast Neoplasms1CTD_human
TgeneKRASC3714758Juvenile psoriatic arthritis1CTD_human
TgeneKRASC3854181Nevus sebaceous1ORPHANET
TgeneKRASC4552091Polyarthritis, Juvenile, Rheumatoid Factor Negative1CTD_human
TgeneKRASC4552097Nevus Sebaceus of Jadassohn1CTD_human;GENOMICS_ENGLAND
TgeneKRASC4704862Polyarthritis, Juvenile, Rheumatoid Factor Positive1CTD_human